Roller coaster stock: Sam Chun Dang Pharm surges over 400%, then plunges amid doubts
Sam Chun Dang Pharm, which once topped the Kosdaq by market capitalization, has been experiencing heightened volatility in recent weeks, drawing intense investor attention, industry officials said Monday. The stock briefly rose to 1.18 million won ($783) per share late last month, buoyed by strong optimism surrounding its oral insulin project and a licensing deal with a U.S. partner, lifting the company to the top of the Kosdaq. However, allegations that the deal had been overstated, along with doubts about the sustainability of the rally, soon sparked controversy and sent the share price tumbling by nearly half within just three days. CEO Chun In-seok, the company’s largest shareholder, sought to contain the fallout by canceling a planned large-scale block sale and holding a press conference. Earlier on Monday, the company said Chun had withdrawn his plan, first disclosed on March 24, to carry out a 250 billion won block sale. He had intended to sell 265,700 shares through after-hours transactions between April 23 and May 22 to raise funds for gift tax and other tax liabilities. Rever
